Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
Posts Tagged ‘NASDAQ:BMRN’
Do Hedge Funds and Insiders Love Alexion Pharmaceuticals, Inc. (ALXN)?
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Hedge Funds Are Crazy About BioMarin Pharmaceutical Inc. (BMRN)
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Is Illumina, Inc. (ILMN) Going to Burn These Hedge Funds?
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times.
Incyte Corporation (INCY), BioMarin Pharmaceutical Inc. (BMRN): Two Biotech Stocks That Could Be on Novartis AG (ADR) (NVS)’s Buyout Radar
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. (ALXN), BioMarin Pharmaceutical Inc. (BMRN): 5 of the World’s Most Ultra-Rare Diseases
There are few times when your doctor or physician will utter the phrase, "I don't know" to a patient, but when you're dealing with the rarest of diseases, then all bets are off...
Aegerion Pharmaceuticals, Inc. (AEGR), ISIS Pharmaceuticals, Inc. (ISIS), BioMarin Pharmaceutical Inc. (BMRN): Orphan Drug Makers – Robust Investment Opportunities
The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases.
Alexion Pharmaceuticals, Inc. (ALXN), Eli Lilly & Co. (LLY): Five Drugmakers With a Lot on the Line
You may or may not have heard, but it's earnings season again.
Exploding Pipeline Makes BioMarin Pharmaceutical Inc. (BMRN) Attractive Takeover Target
The Orphan Drug pipeline of BioMarin Pharmaceutical Inc.
LinkedIn Corp (LNKD), BioMarin Pharmaceutical Inc. (BMRN), ArcelorMittal (ADR) (MT): Don’t Miss These Three Companies With High Earnings-Per-Share Forecasts
Earnings per share, or EPS, is an important metric for investors performs a lot of functions: It helps suggest potential profits on individual shares in a company.
Wells Fargo & Co (WFC), Baxter International Inc. (BAX): Obamacare-Inspired Investment Opportunities
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Dendreon Corporation (DNDN), Johnson & Johnson (JNJ), Medivation Inc (MDVN): The Most Expensive Drugs in the World
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016.
Alexion Pharmaceuticals, Inc. (ALXN), BioMarin Pharmaceutical Inc. (BMRN): What Makes a Good Orphan Drug Investment?
The word “Orphan’ in biotechnology creates excitement! It means that a company has more years of exclusivity on a product and it also indicates that a company’s technology...
Highlights from the Goldman Sachs Group Inc (GS) Healthcare Conference
Healthcare was considered a defensive sector during the 2008–09 recession, but I believe it will continue to perform going forward.
Clovis Oncology Inc (CLVS), Synta Pharmaceuticals Corp. (SNTA): Post-ASCO Movers – Are Any a Buy?
Late last year, Clovis Oncology Inc (NASDAQ:CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show a benefit over chemotherapy...
Clovis Oncology Inc (CLVS): Double Data, Double Stock Price
Plenty of data was presented at the American Society for Clinical Oncology meeting over the weekend, causing the first set of ASCO pops, but Clovis Oncology Inc (NASDAQ:CLVS) ...
Hedge Funds Are Selling BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was in 22 hedge funds' portfolio at the end of the first quarter of 2013.
Alexion Pharmaceuticals, Inc. (ALXN), Vertex Pharmaceuticals Incorporated (VRTX): Orphan Drug Biotechs Do It Best
There are many biotech stocks to choose from that have long-lasting value.
Hedge Funds Are Selling BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was in 24 hedge funds' portfolio at the end of December.
Analyst Roundtable: Any Surprises in Amarin Corporation plc (ADR) (AMRN)’s Fourth Quarter?
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
4 Orphan Drugs Making Waves in 2013: Sanofi SA (ADR) (SNY) and More
Orphan drugs -- medications meant for small patient populations with rare, dangerous diseases -- can be a rewarding business for biotech firms that strike gold.
BioMarin Pharmaceutical Inc. (BMRN) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
BioMarin Pharmaceutical Inc. (BMRN) is a Prime Takeover Target
How many of us as investors want to identify companies that are pioneers in their industry? Is it possible to find commonality across sectors, which factors make specific companies...
